Last reviewed · How we verify
Rosuvastatin, Olmesartan Medoxomil — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Rosuvastatin, Olmesartan Medoxomil (Rosuvastatin, Olmesartan Medoxomil) — Daewoong Pharmaceutical Co. LTD..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rosuvastatin, Olmesartan Medoxomil TARGET | Rosuvastatin, Olmesartan Medoxomil | Daewoong Pharmaceutical Co. LTD. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rosuvastatin, Olmesartan Medoxomil CI watch — RSS
- Rosuvastatin, Olmesartan Medoxomil CI watch — Atom
- Rosuvastatin, Olmesartan Medoxomil CI watch — JSON
- Rosuvastatin, Olmesartan Medoxomil alone — RSS
Cite this brief
Drug Landscape (2026). Rosuvastatin, Olmesartan Medoxomil — Competitive Intelligence Brief. https://druglandscape.com/ci/rosuvastatin-olmesartan-medoxomil. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab